Raj K. Puri - 22 Nov 2024 Form 3 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Regulatory Officer
Signature
/s/ Raj K. Puri
Issuer symbol
IOVA
Transactions as of
22 Nov 2024
Net transactions value
$0
Form type
3
Filing time
02 Dec 2024, 17:25:19 UTC
Next filing
18 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IOVA Common Stock 150,837 22 Nov 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IOVA Stock Options (Right to Buy) 22 Nov 2024 Common Stock 325,000 $12.38 Direct F2
holding IOVA Stock Options (Right to Buy) 22 Nov 2024 Common Stock 35,902 $7.12 Direct F2
holding IOVA Stock Options (Right to Buy) 22 Nov 2024 Common Stock 57,858 $7.12 Direct F2
holding IOVA Restricted Stock Units 22 Nov 2024 Common Stock 120,423 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 3,472 shares of the Issuer's common stock purchased under the Issuer's 2020 Employee Stock Purchase Plan.
F2 Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
F3 The remaining restricted stock units ("RSUs") will vest in equal quarterly installments.
F4 Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

1. On November 22, 2024, Raj K. Puri was promoted to Chief Regulatory Officer from his previous position as Executive Vice President, Regulatory Strategy and Translational Medicine. Dr. Puri joined Iovance Biotherapeutics, Inc. (the "Issuer") in March 2022.